A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers.

A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers. Abstract Text:

Sanjay Goel,Kavita Desai,Manuel Macapinlac,Scott Wadler,Gary Goldberg,Abbie Fields,Mark Einstein,Fabio Volterra,Benny Wong,Russell Martin,Sridhar Mani,

PURPOSE: GEM231 is a second-generation antisense oligonucleotide targeting the mRNA of the R1alpha regulatory subunit of cAMP dependent protein kinase A. Preclinical studies have demonstrated synergistic antitumor activity when GEM231 is combined with docetaxel. This trial assesses the safety of this combination. EXPERIMENTAL DESIGN: Docetaxel was administered once every three weeks (one-cycle) at doses between 50-75 mg/m2. GEM231 was administered twice weekly at 220 mg/m2 for 3 (schedule-A), or 2 (schedule-B) weeks. RESULTS: Twenty patients with chemotherapy-refractory advanced cancer received a total of 39 cycles of therapy. Six patients in schedule-A received docetaxel 50 mg/m2, and 14 patients in schedule-B received docetaxel 50-75 mg/m2. In schedule-A, 2 of 6 patients developed cycle-1 dose limiting toxicity (DLT)-grade-3 fatigue or grade-3 serum transaminase elevation. In schedule-B, 1 of 4 patients developed cycle-1 DLT at the highest dose of docetaxel tested (75 mg/m2)--grade-3 febrile neutropenia. Subsequent dose escalations were not pursued since the overall incidence of grade-3 toxicities (including those that occurred after cycle 1) was 75%, and this dose was close to the single agent MTD of docetaxel. Grade-3 toxicities included fatigue (2 patients), transaminase elevation (4 patients), and altered mentation (1 patient). The mean post-infusion aPTT was significantly higher than the pre-infusion value [14.8 seconds; p<0.001]; however, there were no hemorrhagic episodes. CONCLUSIONS: The recommended dose for further development of the combination of docetaxel and GEM231 is 75 mg/m2 and 220 mg/m2, respectively. It is important to administer GEM231 twice weekly for 2 consecutive weeks followed by a one-week break.

A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers. Publishing Authors By Initials

S Goel,K Desai,M Macapinlac,S Wadler,G Goldberg,A Fields,M Einstein,F Volterra,B Wong,R Martin,S Mani,

For similar organic chemicals: hydrocarbons: hydrocarbons, cyclic: hydrocarbons, alicyclic: cycloparaffins: cyclodecanes: taxoids research abstracts see: organic chemicals: hydrocarbons: hydrocarbons, cyclic: hydrocarbons, alicyclic: cycloparaffins: cyclodecanes: taxoids research

PUBMED ID PMID:

MEDLINE DATE:

A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Investigational new drugs

VOLUME: 24

Page Numbers: 125-34

Journal Abbreviation:

ISSN: 0167-6997

DAY: 27

MONTH: Mar

YEAR: 2006

A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8309330

A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers. Keywords Mesh Terms:

KEYWORDS: Taxoids

MESH TERMS: adverse effects

Chemical & Substance for Abstract: A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers. Information

Substance Name: docetaxel

Registry Number: 114977-28-5

Grant and Affiliation Information for A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers.

AFFILIATION: Albert Einstein Cancer Center, Bronx, NY, USA. sgoel@montefiore.org

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Invest New Drugs

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers Related Publications

• A conceptual model of people's approach to sanitation.
• A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers.
• A review of the clinical significance of tissue hypoxia measurements in lower extremity wound management.
• Agranulocytosis induced by nonchemotherapy drugs.
• Arteriographic evaluation of the femoral bifurcation value of the ipsilateral anterior oblique projection.
• Base-mediated reaction of hydrazones and nitroolefins with a reversed regioselectivity: a novel synthesis of 1,3,4-trisubstituted pyrazoles.
• Carcinoma of the tail of the pancreas: an unusual CT appearance.
• Complications of catheter cerebral arteriography: analysis of 5,000 procedures. I. Criteria and incidence.
• Computer-assisted radiology management systems: principles derived from hard experience.
• GAP-43 is key to mitotic spindle control and centrosome-based polarization in neurons.
• Health issues in the Arab American community. Summary report: HIV/AIDS in the Middle East and North Africa.
• Hope for Tamil heads.
• Kidney business as usual.
• Mild radioiodination of insulin with dichloramine-T.
• Molecular detection and antimicrobial resistance of diarrheagenic Escherichia coli strains isolated from diarrheal cases.
• Neurospheres derived from human embryoid bodies treated with retinoic Acid show an increase in nestin and ngn2 expression that correlates with the proportion of tyrosine hydroxylase-positive cells.
• Outcome measurements in wound healing are not inclusive: a way forward.
• Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineeredTM monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors.
• Photosynthesis in the ears of five varieties of wheat.
• RAPORT radiology system: results of clinical trials.
• Reference range of thyroid hormones in normal Indian school-age children.
• Regioselective synthesis of 1,3,5-tri- and 1,3,4,5-tetrasubstituted pyrazoles from N-arylhydrazones and nitroolefins.
• Role of nitric oxide in the gastro-protective effect of lithium.
• Shoulder MR arthrography: which patient group benefits most?
• Surgical reconstruction of the hand with triple nerve palsy.
• The comparison of the diuretic and natriuretic efficacy of continuous and bolus intravenous furosemide in patients with chronic kidney disease.
• The cradle baby scheme.
• The role of integrated education for blind children.
• The significance of measurements in wound healing: where do we go from here?
• [History of hygiene. Continuity and changes of hygienic ideas from antiquity to the 19th century]